210832-82-9

Basic information

• Product Name: BUTTPARK 146\50-46
• Synonyms: BUTTPARK 146\50-46;2,2-Dibromo-1-(4-morpholin-4-ylphenyl)ethanone;2,2-dibromo-1-[4-(morpholin-4-yl)phenyl]ethan-1-one
• CAS NO: 210832-82-9
• Molecular Formula: C₁₂H₁₃Br₂NO₂
• Molecular Weight: 363.05
• Mol File: 210832-82-9.mol

Chemical Properties

• Boiling Point: 437.3±45.0 °C(Predicted)
• Appearance: /
• Density: 1.720±0.06 g/cm3(Predicted)
• PKA: 1.13±0.40(Predicted)
• CAS DataBase Reference: BUTTPARK 146\50-46(CAS DataBase Reference)
• NIST Chemistry Reference: BUTTPARK 146\50-46(210832-82-9)
• EPA Substance Registry System: BUTTPARK 146\50-46(210832-82-9)

Safety Data

• Hazardous Substances Data: 210832-82-9(Hazardous Substances Data)

Upstream product

• 39910-98-0 4-morpholinoacetophenone 

Downstream Products

• 210832-85-2 2-bromo-1-(4-(piperidin-1-yl)-phenyl)ethan-1-one 
• 924899-53-6 2-(4-morpholinophenyl)-2-oxoethyl acetate 

Relevant articles and documents

Synthesis and biological evaluation of quinoline salicylic acids as P-selectin antagonists

Leukocyte recruitment of sites of inflammation and tissue injury involves leukocyte rolling along the endothelial wall, followed by firm adherence of the leukocyte, and finally transmigration of the leukocyte across cell junctions into the underlying tissue. The initial rolling step is mediated by the interaction of leukocyte glycoproteins containing active moieties such as sialyl Lewisx (sLex) with P-selectin expressed on endothelial cells. Consequently, inhibition of this interaction by means of a small molecule P-selectin antagonist is an attractive strategy for the treatment of inflammatory diseases such as arthritis. High-throughput screening of the Wyeth chemical library identified the quinoline salicylic acid class of compounds (1) as antagonists of P-selectin, with potency in in vitro and cell-based assays far superior to that of sLex. Through iterative medicinal chemistry, we identified analogues with improved P-selectin activity, decreased inhibition of dihydrooratate dehydrogenase, and acceptable CYP profiles. Lead compound 36 was efficacious in the rat AIA model of rheumatoid arthritis.

A facile protocol for the convenient preparation of amino-substituted α-bromo- and α,α-dibromo arylmethylketones

Amino-substituted arylmethylketones are selectively brominated in sulfuric acid to afford the corresponding dibromomethylarylketones that are then debrominated with diethylphosphite to give the desired bromomethylarylketones in excellent yield.